BC Innovations | May 12, 2016
Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); tumor necrosis factor receptor 1 (TNFRSF1A; TNFR1; CD120a); HECT domain and ankyrin

Cancer INDICATION: Colorectal cancer; cancer Mouse studies suggest inhibiting TNFRSF1A or RIPK3 could help treat colon and other cancers harboring loss-of-function HACE1 mutations. In a mouse model of HACE1-mutant colon cancer, systemic knockout of TNFRSF1A...
Items per page:
1 - 1 of 1